Both biotech ETFs hold about 30 healthcare names, but their index methods and fees differ enough to shape results for investors weighing sector exposure.
Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.
One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
PINK offers broad active healthcare exposure with lower volatility, while FBT's concentrated biotech play delivered stronger 1-year returns but carries steeper drawdown risk.
FBT has outperformed RSPH by a wide margin recently. The question is whether you want to own the fund that won last year or the one built to hold up over many years.
IXJ offers diversified global exposure at lower cost, while FBT concentrates on biotech with higher volatility and stronger recent returns.
The fund bought $90.7 million of Tarsus Pharmaceuticals as a new position, part of $516.5 million in gross trading and $80.2 million in net buying.
VanEck's lower 0.35% expense ratio appeals to cost-conscious investors, while First Trust's $2.9 billion in assets and equal-weighted approach offer broader diversification across 30 biotech holdings.
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
This is the newest page. Registered accounts read further back.